Losartan Potassium Tablet, Film Coated
Product Images NDC 46708-445

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 46708-445). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Tablets In Hdpe Bottle (Losartan 100mg)

Losartan Potassium 100 mg Tablets, USP film-coated tablet label. The label shows the dosage strength as 100 mg with a package count of 30 tablets. It includes storage instructions, manufacturer details (Alembic Pharmaceuticals Limited, India), and a barcode. The label indicates the product is prescription only (Rx only).*

FDA Label Image

30 Tablets In Hdpe Bottle (Losartan 25mg)

Label for Losartan Potassium Tablets USP 25 mg film-coated tablets by Alembic Pharmaceuticals Limited. The package contains 30 tablets. The label includes storage instructions, dosage note to see accompanying circular, NDC 46708-445-30, and pharmacy dispensing instructions. Barcode and manufacturing information are visible.*

FDA Label Image

30 Tablets In Hdpe Bottle (Losartan 50mg)

Losartan Potassium Tablets USP 50 mg film-coated tablets label. The label includes storage instructions, manufacturer information (Alembic Pharmaceuticals Limited, Gujarat, India), a barcode, and states a package size of 30 tablets. The label emphasizes prescription use (Rx only) and refers to an attached patient information leaflet.*

FDA Label Image

Figure 1 (Losartan Fig1)

A line graph comparing the percentage of patients with the primary endpoint over a study period of 66 months between Losartan Potassium Tablets and Atenolol. The x-axis represents study months, while the y-axis shows the percentage of patients with the primary endpoint. The graph indicates an adjusted risk reduction of 13% for Losartan Potassium Tablets compared to Atenolol.*

FDA Label Image

Figure 2 (Losartan Fig2)

Line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months for Atenolol and Losartan Potassium Tablets. The graph shows a lower cumulative percentage of stroke events for Losartan Potassium Tablets versus Atenolol, indicating an adjusted risk reduction of 25% with statistical significance (p=0.001).*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' presenting two forest plots comparing Losartan potassium tablets and Atenolol for primary composite and stroke endpoints. The charts show event rates, hazard ratios, and 95% confidence intervals across demographic categories like age, gender, race, ischemic heart status, diabetes, and cardiovascular history.*

FDA Label Image

Figure 4 (Losartan Fig4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium tablets and placebo. The graph shows a lower event rate for Losartan Potassium compared to placebo, with a noted risk reduction of 16.1% and p-value of 0.022. The x-axis represents time in months, and the y-axis represents the percentage of patients with events.*

FDA Label Image

Structure (Losartan Str)

Chemical structure diagram of losartan potassium, depicting the molecular arrangement including a chlorine-substituted imidazole ring, a biphenyl group, and the potassium ion associated with the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.